Elsevier

Brain Research Reviews

Volume 48, Issue 2, April 2005, Pages 370-378
Brain Research Reviews

Review
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology

https://doi.org/10.1016/j.brainresrev.2004.12.026Get rights and content

Abstract

The extracellular deposition of amyloid (A) peptides in plaques, and neurofibrillary tangles are the two characteristic pathological features of Alzheimer's disease (AD). Plaques are surrounded by activated astrocytes and microglia, to study the relation between amyloid neuropathology and inflammation, we examined the changes in amyloid pathology in the hippocampus following three different treatments aimed at reducing the amyloid burden. (1) To investigate the effects of long-term cholinergic deafferentation, we lesioned the fimbria-fornix pathway in our AD-model mice at 7 months of age, and 11 months post-lesion the mice were sacrificed for histopathological analysis. The fimbria-fornix transection resulted in a substantial depletion of cholinergic markers in the hippocampus, but the lesion did not result in an alteration in hippocampal A deposition and inflammation (i.e., numbers or staining density of astrocytes and microglia). (2) To investigate the effects of estrogen, we ovariectomized mice and treated them with estrogen (sham-lesion, zero dose, low dose, and high dose) and studied the pathology at different postsurgery intervals. Estrogen depletion (i.e., ovariectomy) or estrogen replacement did not affect A deposition or inflammation at any time point. (3) In the final studies, we treated mice with flurbiprofen and an NO-donating derivative of flurbiprofen (HCT 1026) for several months (from 6 till 14 months of age), and studied the A pathology and inflammation in the brain. Sham treatment, flurbiprofen, and the low-dose HCT 1026 did not affect pathology; however, a higher dose of HCT 1026 reduced both A load and amount of microglial activation surrounding plaques.

Introduction

Alzheimer disease (AD), the most common cause of dementia in the elderly [8], is characterized pathologically by the presence of large numbers of neuritic plaques and neurofibrillary tangles [2], [3]. Neuritic plaques primarily consist of deposits of amyloid β (Aβ), a 39–43 amino acid peptide that is derived through the processing of amyloid precursor protein (APP), i.e., when APP is sequentially cleaved by the β- and γ-secretase (e.g., [11], [28]). Most AD cases are sporadic (e.g., [12], [24]); however, approximately 5% of AD cases are familial. Some of these familial cases are early-onset, and those are caused by mutations in the genes for APP, presenilin 1 and 2 (PS1 and PS2 [24]). These mutations have been shown to alter APP metabolism and they lead to an increase of the Aβ levels in the brain [12], [24], [27], implicating a central role for APP processing and the concomitant increase in Aβ levels in the pathogenesis of AD.

Transgenic mice expressing mutated human genes associated with familial forms of AD offer a powerful model to study the role of Aβ in the development of AD pathology (e.g., [15], [25]). The present study employs double transgenic mice expressing both human APPswe and PS1-A246E mutations (APP/PS1 mice [1]). These mice develop elevated levels of the highly fibrillogenic Aβ42 peptide, and get amyloid plaques starting around the age of 9 months [1], [20], [32]. The first amyloid plaques are present in the subiculum (and caudal cortex), and later these deposits extend to the hippocampus and all cortical areas [20], [32]. This feature is somewhat similar to the early stages of AD pathology, in which the amyloid plaques are also largely restricted to the medial temporal cortical structures [3]. We noted that in these mice, early in the development of pathology there are predominantly dense plaques, and that diffuse deposits develop later [31], [32]. However, it is still unknown how this amyloid deposition and the changes in the neuropathology are related to the change(s) in the processing of APP, and the development of AD. It has been suggested that the earliest changes in AD are present in the cholinergic basal forebrain (e.g., [4], [9]); therefore, we hypothesized that lesioning the cholinergic input to the hippocampal formation in these mice would allow us to examine the possible correlation between Aβ deposition, inflammation and the level of acetylcholine. Thus, we transected the fimbria-fornix (FFX-lesion); our results show that FFX-lesions did not change the deposition of Aβ [21], neither did it change the number of activated glial cells surrounding amyloid plaques in the brains of these animals.

In our experiments, we noted that there were significant differences in the Aβ load between males in female mice [32]; therefore, we hypothesized that manipulating the levels of estrogen in female mice would affect amyloid pathology. Thus, we ovariectomized female mice and gave them estrogen replacement therapy (i.e., zero, low, and high estrogen levels); our results indicated that this did not change amyloid load pathology [13], [16]. Our analysis of the number of activated glial cells surrounding amyloid plaques in these mice also showed no significant changes in inflammation.

We noted that in these mice, early in the development of pathology, there are predominantly dense plaques, and that diffuse deposits develop later [30], [31]. Whereas plaques are surrounded by activated astrocytes and microglial cell, the diffuse deposits do not show this activation of glial cells [30], [31]. Furthermore, even the earliest plaques are surrounded by activated astrocytes and microglia; therefore, we hypothesized that treatment of these mice with a non-steroidal anti-inflammatory drug (NSAID) from an early age would decrease amyloid pathology. For this study, we used four groups of female mice; they were treated with the NSAID from 8 months of age (i.e., before pathology is present) for 6 months, one group was on the Control diet, one group on Flurbiprofen, one group on a low HCT 1026 (a NO donating form of flurbiprofen), and one group was on a high HCT 1026 diet. Both the pathology, i.e., the Aβ load, and the amount of activated microglia were significantly reduced in the mice treated with high dose of HCT 1026 compared to the other groups.

Section snippets

Animals

Male and female APP and PS1 double transgenic mice (AP mice, n = 48) and non-transgenic littermate controls (Control mice, n = 48) were used in the present study. The mice were generated from matings between APPswe transgenic mice and HuPS1-A246E transgenic mice. These mice were originally produced at the Johns Hopkins University ([1]; Baltimore, MD, USA) and are now bred locally. Throughout the experiments, the animals were housed individually in a controlled environment (temperature 22 °C,

Experiment 1, cholinergic manipulations

Part of the data (Aβ load and AChE measurements) from the FFX lesion experiments have been published before [20], [21]; therefore, we will only shortly describe those data and focus on the results from the stainings with astrocytic and microglial markers. At 17 months of age (i.e., 11 months post FFX lesion), the lesion resulted in a nearly complete loss of the hippocampal AChE-positive fibers (Fig. 1B). The decrease in AChE staining was higher in the hippocampus than in the subiculum; further,

Discussion

We investigated the effects of different anti-AD treatments on the amount of amyloid deposition, and on the inflammation surrounding Aβ deposits in transgenic mice coexpressing mutated human APP and PS1 genes [1].

We found that a near-complete cholinergic denervation of the hippocampus [19] did not significantly affect hippocampal APP levels and Aβ deposition in the hippocampus in our APP + PS1 transgenic mice. Further, our data show that the transection of the fimbria-fornix pathway does not

Acknowledgments

We thank Dr. Egon von Schnier for his excellent comments on an earlier version of this manuscript, Pasi Miettinen for his assistance with the histology. We thank K. Beyreuther for the W0-2 antibody; flurbiprofen and 2-fluoro-a-methyl[1.1′-biphenyl]-4-acetic acid 4-(nitrooxy)butyl ester (HCT 1026) were provided by the Nicox Research Institute (Bresso, Milan, Italy). This study was supported by a grant from the Pääivikki and Sakari Sohlberg Foundation and TEKES project 40043/01.

References (34)

  • T. Thomas et al.

    Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction

    Microvasc. Res.

    (2001)
  • T. van Groen et al.

    Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions

    Neuroscience

    (2003)
  • J. Wang et al.

    Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice

    Neurobiol. Dis.

    (2003)
  • J. Wegiel et al.

    The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice

    Neurobiol. Aging

    (2001)
  • H. Braak et al.

    Neuropathological stageing of Alzheimer-related changes

    Acta Neuropathol.

    (1991)
  • H. Braak et al.

    Evolution of neuronal changes in the course of Alzheimer's disease

    J. Neural Transm.

    (1998)
  • J.T. Coyle et al.

    Alzheimer's disease: a disorder of cortical cholinergic innervation

    Science

    (1983)
  • Cited by (0)

    View full text